期刊文献+

HPLC法测定非诺贝特缓释片中非诺贝特

Determination of fenofibrate in Fenofibrate Sustained-release Tablets by HPLC
原文传递
导出
摘要 目的采用HPLC法测定非诺贝特缓释片中非诺贝特。方法采用DikmaC18色谱柱(200mm)〈4.6mm,5μm);流动相:甲醇-水(90:10);检测波长:288nm;柱温:25℃;体积流量:1.0μL/mim进样量10μL。结果非诺贝特在2.0~12.0μg/mL与其峰面积呈良好的线性关系(F=0.9999);检测限和定量限分别为10、30ng/mL;平均回收率为99.86%,RSD值为0.72%(n=9)。结论该方法准确、简便,可用于非诺贝特缓释片中非诺贝特的质量控制。 Objective To establish an HPLC method for determining fenofibrate in Fenofibrate Sustained-release Tablets. Methods HPLC was carried out on a Dikma Cls column (200 mm x 4.6 mm, 5 μm) with methanol - water (90 : 10) as mobile phase. The detection wavelength was set at 288 nm. The injection volume was 20 μL at the flow rate of 1.0 μL/min. The temperature of column was set at 25 ℃. Results There were good linear relationship of fenofibrate in the range of 2 - 12μg/mL (r = 0.999 9). The limits of detection and quantitation were 10 and 30 ng/mL, respectively. The average recoveries was 99.86% with RSD value of 0.72% (n = 9). Conclusion The method is accurate and simnle for aualitv control of fenofibrate in Fenofibrate Sustained-release Tablets.
出处 《现代药物与临床》 CAS 2014年第5期497-499,共3页 Drugs & Clinic
基金 国家重点基础研究发展计划(973计划)项目(2012CB724001)
关键词 非诺贝特缓释片 非诺贝特 高效液相色谱 Fenofibrate Sustained-release Tablets fenofibrate HPLC
  • 相关文献

参考文献4

二级参考文献60

  • 1全球药品研发进展(2006.7)[J].中国医药工业杂志,2007,38(1). 被引量:1
  • 2Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action offibrateson lipid and lipoprotein metabolism[J]. Circulation, 1998, 98 (19) : 2088. 被引量:1
  • 3Playford DA, Watts GF, Best JD, el al. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus[J]. Am J Cardiol, 2002,90(11) : 1254. 被引量:1
  • 4Ogata T, Miyauchi T,Irukayarrka-Tomobe Y, et al. The peroxisome proliferator-activated receptor alpha activator fenofibrate inhibits endothelin- 1-induced cardiac fibroblast proliferation[ J]. J Cantiovasc Pharmacol, 2004,44(Suppl 1 ) : $279. 被引量:1
  • 5Zambon A, Gervois P, Pauletto P, et al. Modulation of hepatic inflamnkatory risk markers of cardiovascular diseases by PPARa activators: clinical and experimental evidence [ J ]. Arterioscler Thromb Vase Biol, .2006, 26(5):977. 被引量:1
  • 6Kooistra T, Verschuren L, Koenig W, et al. Fenofibrate reduces atherogenesis in ApoE * 3 leiden mice-evidence for multiple antiatherogenic effects besides lowering plasma cholesterol[ J]. Arterioseler Thromb Vasc Biol,2006,26(10) :2322. 被引量:1
  • 7Kim J, Aim JH, Kim JH, et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway[J]. Exp Eye Res, 2007, 84(5):886. 被引量:1
  • 8Chanda D, Lee CH, Kim YH, et al. Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate activated protein kinase dependent induction of orphan nuclear receptor small hetert-timer partner [ J ]. Hepatology, 50 ( 3 ) :880. 被引量:1
  • 9Murakami H, Murakanti R, Kambe F, et al. Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC[J]. Biochem Biophys Res Commun, 2006, 341 (4) : 973. 被引量:1
  • 10Genest J, Froblich J, Steinvr G, etal. Effect of fenofibrate-mediated increase in plasma homceysteine on the progression of coronary artery disease in type 2 diabetes mellitus[J] .Am J Cardio,2004, 93(7):848. 被引量:1

共引文献369

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部